BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that in honor of Celiac Disease Awareness Month in May, it will partner with Celiac Journey, a celiac disease patient advocacy organization, to share an awareness digital display on the Nasdaq Tower
LAS VEGAS, NV / ACCESSWIRE / April 29, 2024 / Planet MicroCap presents the Planet MicroCap Showcase: VEGAS taking place on April 30 - May 2, 2024, where 96 MicroCap public and private companies will be presenting at the Paris Hotel & Casino in Las ...
Paper highlights findings on impact of a gluten-containing diet on serologic status in celiac diseaseBOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced research generated from two previously completed Phase 2 clinical trials of latiglutenase has be